Transgene Biotek Limited (TRABI.BO)
INR 7.34
(-0.53%)
INR 7.34
(-0.53%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -7.08 Million INR | 88.19% |
| 2022 | -60.02 Million INR | 42.21% |
| 2021 | -103.87 Million INR | 0.45% |
| 2020 | -104.35 Million INR | 3.02% |
| 2019 | -107.6 Million INR | -1.73% |
| 2018 | -105.77 Million INR | 11.82% |
| 2017 | -119.95 Million INR | 40.29% |
| 2016 | -200.88 Million INR | 6.73% |
| 2015 | -215.38 Million INR | -12.56% |
| 2014 | -191.35 Million INR | 85.66% |
| 2013 | -1.33 Billion INR | -6457.84% |
| 2012 | -20.34 Million INR | -111.83% |
| 2011 | 171.93 Million INR | 297.06% |
| 2010 | -87.25 Million INR | -768.33% |
| 2009 | 13.05 Million INR | 0.49% |
| 2008 | 12.99 Million INR | -11.56% |
| 2007 | 14.69 Million INR | 7.5% |
| 2006 | 13.66 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -4.35 Million INR | -49.5% |
| 2023 FY | -7.08 Million INR | 88.19% |
| 2023 Q2 | -1.44 Million INR | 4.19% |
| 2023 Q1 | -1.5 Million INR | 89.77% |
| 2023 Q4 | -2.91 Million INR | -122.89% |
| 2023 Q3 | -1.3 Million INR | 9.39% |
| 2022 FY | -60.02 Million INR | 42.21% |
| 2022 Q2 | -17.68 Million INR | -27.5% |
| 2022 Q3 | -13.77 Million INR | 22.08% |
| 2022 Q1 | -13.86 Million INR | 46.03% |
| 2022 Q4 | -14.7 Million INR | -6.7% |
| 2021 Q4 | -25.69 Million INR | 2.31% |
| 2021 Q1 | -25.98 Million INR | 2.64% |
| 2021 FY | -103.87 Million INR | 0.45% |
| 2021 Q3 | -26.3 Million INR | -1.53% |
| 2021 Q2 | -25.9 Million INR | 0.32% |
| 2020 FY | -104.35 Million INR | 3.02% |
| 2020 Q1 | -25.7 Million INR | 5.21% |
| 2020 Q2 | -26.06 Million INR | -1.42% |
| 2020 Q3 | -24.49 Million INR | 6.02% |
| 2020 Q4 | -26.69 Million INR | -8.96% |
| 2019 FY | -107.6 Million INR | -1.73% |
| 2019 Q4 | -27.11 Million INR | -4.85% |
| 2019 Q3 | -25.86 Million INR | 2.68% |
| 2019 Q2 | -26.57 Million INR | -1.19% |
| 2019 Q1 | -26.26 Million INR | 0.23% |
| 2018 Q4 | -26.32 Million INR | 0.18% |
| 2018 FY | -105.77 Million INR | 11.82% |
| 2018 Q3 | -26.36 Million INR | -3.47% |
| 2018 Q2 | -25.48 Million INR | -2.43% |
| 2018 Q1 | -24.88 Million INR | 0.0% |
| 2017 FY | -119.95 Million INR | 40.29% |
| 2016 FY | -200.88 Million INR | 6.73% |
| 2016 Q4 | - INR | 0.0% |
| 2015 FY | -215.38 Million INR | -12.56% |
| 2015 Q4 | - INR | 0.0% |
| 2014 FY | -191.35 Million INR | 85.66% |
| 2013 FY | -1.33 Billion INR | -6457.84% |
| 2012 Q3 | -3.64 Million INR | -165.6% |
| 2012 Q2 | -1.37 Million INR | 73.01% |
| 2012 Q1 | -5.08 Million INR | 0.0% |
| 2012 FY | -20.34 Million INR | -111.83% |
| 2012 Q4 | -147.39 Million INR | -3944.84% |
| 2011 FY | 171.93 Million INR | 297.06% |
| 2010 FY | -87.25 Million INR | -768.33% |
| 2009 FY | 13.05 Million INR | 0.49% |
| 2008 FY | 12.99 Million INR | -11.56% |
| 2007 FY | 14.69 Million INR | 7.5% |
| 2006 FY | 13.66 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alfavision Overseas (India) Limited | 9.28 Million INR | 176.365% |
| Biocon Limited | 50.83 Billion INR | 100.014% |
| Blue Jet Healthcare Limited | 3.37 Billion INR | 100.21% |
| Concord Biotech Limited | 6.26 Billion INR | 100.113% |
| Dishman Carbogen Amcis Limited | -13.9 Million INR | 49.0% |
| FERMENTA BIOTECH LIMITED | 1.06 Billion INR | 100.664% |
| GENOMIC VALLEY BIOTECH LIMITED | 1.27 Million INR | 655.673% |
| Lyka Labs Limited | 29.13 Million INR | 124.336% |
| Panacea Biotec Limited | -309.7 Million INR | 97.711% |
| SAMSRITA LABS LIMITED | -1.49 Million INR | -373.427% |
| Servoteach Industries Limited | -785.00 INR | -902957.325% |
| SMS Lifesciences India Limited | 359.47 Million INR | 101.972% |
| Supriya Lifescience Limited | 1.57 Billion INR | 100.451% |
| Syngene International Limited | 14.02 Billion INR | 100.051% |
| TAKE Solutions Limited | -213.49 Million INR | 96.679% |
| Titan Biotech Limited | 315.89 Million INR | 102.244% |
| Vanta Bioscience Limited | -31.83 Million INR | 77.734% |